LAVAL, QC, Nov. 12, 2018 /PRNewswire/ - Prometic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced
today that it will report its financial results for the third
quarter ended September 30, 2018 on
Wednesday November 14, 2018 after
market close.
Prometic will host a conference call at 11:00am (ET) on
Thursday November 15, 2018. The
telephone numbers to access the conference call are 1-888-231-8191
and 647-427-7450. An audio replay of the call will be available as
of Thursday November 15, 2018 at
2:00pm (ET). The numbers to access
the audio replay are 416-849-0833 and 1-855-859-2056 using the
following password (1190238).
A live audio webcast of the conference call will be available
via:
https://event.on24.com/wcc/r/1875420/A5BAEDCB1DAD05CDD9CCBE59D000BB89
About Prometic Life Sciences Inc.
Prometic (www.prometic.com) is a publicly traded (TSX symbol:
PLI) (OTCQX symbol: PFSCF) biopharmaceutical corporation with two
drug discovery platforms focusing on unmet medical needs. The first
platform (small molecule therapeutics) stems from the discovery of
two receptors which we believe are at the core of how the body
heals: namely, promoting tissue regeneration and scar resolution as
opposed to fibrosis. One of the lead drug candidates emerging from
this platform, PBI-4050, is expected to enter pivotal phase 3
clinical trials for the treatment of Idiopathic Pulmonary Fibrosis
(IPF). The second drug discovery and development platform
(plasma-derived therapeutics) leverages Prometic's experience in
bioseparation technologies used to isolate and purify
biopharmaceuticals from human plasma. The Corporation's primary
goal with respect to this second platform is to address unmet
medical needs with therapeutic proteins not currently commercially
available, such as Ryplazimâ„¢ (plasminogen). We are also leveraging
this platform's higher recovery yield potential to advance
established plasma-derived therapeutics such as Intravenous
Immunoglobulin (IVIG). The Corporation also provides access to its
proprietary bioseparation technologies to enable pharmaceutical
companies in their production of non-competing biopharmaceuticals.
Recognized as a bioseparations expert, the Corporation derives
revenue from this activity through sales of affinity chromatography
media which contributes to offset the costs of its own R&D
investments.
We are headquartered in Laval, Quebec
(Canada) and have R&D facilities in Canada, the United
Kingdom ("UK") and the United
States ("USA"), manufacturing facilities in Canada and the Isle
of Man and corporate and business development activities in
Canada, the USA, and Europe.
Forward Looking Statements
This press release contains forward-looking statements about
Prometic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, Prometic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in
Prometic's Annual Information Form for the year ended December 31, 2017, under the heading "Risk and
Uncertainties related to Prometic's business". As a result, we
cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by
applicable securities laws and regulations. All amounts are in
Canadian dollars unless indicated otherwise.
View original
content:http://www.prnewswire.com/news-releases/prometic-to-report-its-third-quarter-2018-financial-results-and-hold-conference-call--webcast-300748665.html
SOURCE ProMetic Life Sciences Inc.